{
  "schema_version": "0.4",
  "ir_kind": "hl",
  "metadata": {
    "title": "Morphogen addition schedule",
    "source": {
      "type": "paper",
      "id": "s41592-025-02927-5.pdf"
    }
  },
  "resources": {
    "materials": [
      {
        "id": "m1",
        "name": "CHIR99021 (CHIR, WNT pathway activator)"
      },
      {
        "id": "m2",
        "name": "XAV939 (WNT pathway inhibitor)"
      },
      {
        "id": "m3",
        "name": "rh‑SHH/CS24II (SHH)"
      },
      {
        "id": "m4",
        "name": "purmorphamine"
      },
      {
        "id": "m5",
        "name": "FGF‑8B (FGF8)"
      },
      {
        "id": "m6",
        "name": "RA"
      },
      {
        "id": "m7",
        "name": "rh‑BMP‑4 (BMP4)"
      },
      {
        "id": "m8",
        "name": "rh‑BMP‑7 (BMP7)"
      }
    ],
    "containers": [],
    "equipment": [],
    "samples": [
      {
        "id": "culture1",
        "name": "Cell culture",
        "type": "cell_culture"
      }
    ],
    "data": []
  },
  "protocol": {
    "steps": [
      {
        "id": "s1",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "note": "Morphogen treatments added at early time points (days 0–3) using CHIR99021 (CHIR, WNT pathway activator), XAV939 (WNT pathway inhibitor), rh‑SHH/CS24II (SHH), purmorphamine, FGF‑8B (FGF8), RA, rh‑BMP‑4 (BMP4) and rh‑BMP‑7 (BMP7)."
        }
      },
      {
        "id": "s2",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "note": "Morphogen treatments added at intermediate time points (days 10–13) using CHIR99021 (CHIR, WNT pathway activator), XAV939 (WNT pathway inhibitor), rh‑SHH/CS24II (SHH), purmorphamine, FGF‑8B (FGF8), RA, rh‑BMP‑4 (BMP4) and rh‑BMP‑7 (BMP7)."
        }
      },
      {
        "id": "s3",
        "op": "annotate",
        "inputs": [],
        "outputs": [],
        "params": {},
        "annotations": {
          "note": "Morphogen treatments added at later intermediate time points (days 14–17) using CHIR99021 (CHIR, WNT pathway activator), XAV939 (WNT pathway inhibitor), rh‑SHH/CS24II (SHH), purmorphamine, FGF‑8B (FGF8), RA, rh‑BMP‑4 (BMP4) and rh‑BMP‑7 (BMP7)."
        }
      }
    ],
    "start_step_id": "s1",
    "edges": [
      {
        "from": "s1",
        "to": "s2"
      },
      {
        "from": "s2",
        "to": "s3"
      }
    ],
    "detail_level": 0
  }
}